Home>Latest
-
December 16, 2021
Ningbo offers incentives for Spring Festival
A maximum allowance of 500 yuan ($78.60) per person will be given to non-local employees who remain in Ningbo, Zhejiang province, to celebrate Spring Festival.
-
December 16, 2021
Zhejiang city ups COVID threat in five areas
Risk level for COVID-19 in five areas in Shangyu district in Shaoxing, a city in northern Zhejiang, hit by the ongoing pandemic, was raised to the highest level on Wednesday, local health authorities said.
-
December 15, 2021
Steady growth for China's economy in Nov: NBS
The Chinese economy maintained a steady recovery last month, with major macro indicators staying within a reasonable range, the National Bureau of Statistics said on Wednesday.
-
December 15, 2021
Zhejiang beefs up nucleic acid tests
A 52-year-old patient with severe COVID-19 symptoms in Ningbo, Zhejiang province, is being treated in a hospital with other patients who have mild symptoms caused by the highly transmissible Delta variant.
-
December 15, 2021
Sea-rail route helps speed up overseas shipments from western China
A smooth trade and logistics route-the New International Land-Sea Trade Corridor-linking western China and the world shows how the nation can achieve a higher level of inland opening-up and help its western region further integrate into the global economy.
-
December 15, 2021
Parcel delivery industry urged to avoid 'rat race'
The regulator of China's booming parcel delivery industry has urged enterprises in the sector to maintain good market order, avoid becoming involved in a rat race and better protect couriers' legal rights.
-
December 15, 2021
Ningbo ports' imports, exports hit 1.8t yuan in Jan-Nov
Imports and exports at Ningbo ports in East China's Zhejiang province amounted to 1.87 trillion yuan ($287.7 billion) in the first 11 months of this year, up 23.7 percent year-on-year, according to Ningbo Customs.
-
December 14, 2021
New hope offered to rare disease patients
Early this month, the world's first therapy to treat spinal muscular atrophy, or SMA, a rare genetic disorder that affects muscle control, was added to the National Reimbursement Drug List in China.
